0001415889-24-015336.txt : 20240604
0001415889-24-015336.hdr.sgml : 20240604
20240604162011
ACCESSION NUMBER: 0001415889-24-015336
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240601
FILED AS OF DATE: 20240604
DATE AS OF CHANGE: 20240604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Feeley Kevin
CENTRAL INDEX KEY: 0001944119
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39482
FILM NUMBER: 241018345
MAIL ADDRESS:
STREET 1: C/O SEMA4 HOLDINGS CORP
STREET 2: 333 LUDLOW STREET, NORTH TOWER, 8TH FL.
CITY: STAMFORD
STATE: CT
ZIP: 06902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GeneDx Holdings Corp.
CENTRAL INDEX KEY: 0001818331
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 851966622
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 617 780 8742
MAIL ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Sema4 Holdings Corp.
DATE OF NAME CHANGE: 20210721
FORMER COMPANY:
FORMER CONFORMED NAME: CM Life Sciences, Inc.
DATE OF NAME CHANGE: 20200715
4
1
form4-06042024_080607.xml
X0508
4
2024-06-01
0001818331
GeneDx Holdings Corp.
WGS
0001944119
Feeley Kevin
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST, NORTH TOWER
STAMFORD
CT
06902
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Class A Common Stock
2024-06-01
4
M
0
717
0
A
31553
D
Class A Common Stock
2024-06-03
4
S
0
262
20.55
D
31291
D
Restricted Stock Unit
2024-06-01
4
M
0
717
0
D
Class A Common Stock
717
6456
D
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
/s/ Devin Schaffer, Attorney-in-Fact
2024-06-04